Next Article in Journal
The Dynamics of Developmental and Tumor Angiogenesis—A Comparison
Previous Article in Journal
A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase
Previous Article in Special Issue
Radiation Therapy for the Treatment of Recurrent Glioblastoma: An Overview
Article Menu

Export Article

Open AccessReview
Cancers 2012, 4(2), 379-399;

External Beam Radiotherapy of Recurrent Glioma: Radiation Tolerance of the Human Brain

1,†,* and 2,†
Department of Radiation Oncology, Radiobiology Section, VU University Medical Center, De Boelelaan 1117, P.O. Box 7057, Amsterdam, The Netherlands
EBG MedAustron GmbH., Viktor Kaplan-Strasse 2, A-2700, Wiener Neustadt, Austria
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Received: 2 March 2012 / Revised: 23 March 2012 / Accepted: 29 March 2012 / Published: 5 April 2012
Full-Text   |   PDF [244 KB, uploaded 25 April 2012]   |  


Malignant gliomas relapse in close proximity to the resection site, which is the postoperatively irradiated volume. Studies on re-irradiation of glioma were examined regarding radiation-induced late adverse effects (i.e., brain tissue necrosis), to obtain information on the tolerance dose and treatment volume of normal human brain tissue. The studies were analyzed using the linear-quadratic model to express the re-irradiation tolerance in cumulative equivalent total doses when applied in 2 Gy fractions (EQD2cumulative). Analysis shows that the EQD2cumulative increases from conventional re-irradiation series to fractionated stereotactic radiotherapy (FSRT) to LINAC-based stereotactic radiosurgery (SRS). The mean time interval between primary radiotherapy and the re-irradiation course was shortened from 30 months for conventional re-irradiation to 17 and 10 months for FSRT and SRS, respectively. Following conventional re-irradiation, radiation-induced normal brain tissue necrosis occurred beyond an EQD2cumulative around 100 Gy. With increasing conformality of therapy, the smaller the treatment volume is, the higher the radiation dose that can be tolerated. Despite the dose escalation, no increase in late normal tissue toxicity was reported. On basis of our analysis, the use of particle therapy in the treatment of recurrent gliomas, because of the optimized physical dose distribution in the tumour and surrounding healthy brain tissue, should be considered for future clinical trials. View Full-Text
Keywords: equivalent total dose (EQD2); re-irradiation; brain; glioma; late side effects equivalent total dose (EQD2); re-irradiation; brain; glioma; late side effects

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Sminia, P.; Mayer, R. External Beam Radiotherapy of Recurrent Glioma: Radiation Tolerance of the Human Brain. Cancers 2012, 4, 379-399.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top